Double IOP system effective in patients with macular degeneration
The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.
The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.
Luis Amselem from the Hospital General Universitario, Valencia, Spain and colleagues evaluated the efficacy of a standard double IOP system in patients with low vision and central scotoma due to macular degeneration. The interventional, prospective, non-comparative case series included 13 consecutive surgical procedures in 10 patients.
At 12-months follow-up the difference between pre- and postoperative BCVA, refraction, position of IOLs, endothelial cell density and occurrences of postoperative complications were evaluated.
At 12-months, mean BCVA was 0.68 logMAR compared with 1.37 logMAR preoperatively. Mean best corrected clinical gain was 44%.
No statistically significant difference between the clinically evaluated and theoretically calculated residual refractions was recorded and there were no intraoperative or postoperative complications.
